Point-of-care technology to provide risk assessment for Covid-19
Salcit Technologies Private Limited, Hyderabad, Telangana, India
Diagnostic technologies for identification of SARS-CoV-2 from human nasal, buccal, or saliva samples
Tech Brief: Swaasa™ is a rapid point-of-care technology to provide risk assessment for Covid-19. The system captures and analyses the ‘audio signatures’ of a patient’s cough using proprietary machine learning and artificial intelligence (AI) algorithms to analyze respiratory diseases. Now the software has been enhanced to provide risk assessment for COVID-19.
Early-stage Startup (Seed)
FIGURES OF MERIT Value Proposition: The impact our system delivers is this: Self-screening by individuals and remote monitoring by healthcare providers to identify risk to stop transmissions chains. The solution (a) needs no equipment/consumables (b) accessible from anywhere (c) anyone can self-assess (d) gives results in < 10 secs (e) costs < $0.15/assessment (f) scaled for 500 million assessments/day. Commercial partners Group1: Public Health official / General Physician / Pulmonologist / working in a health center / private clinic, and (User) Nursing staff / a paramedical practitioner. Value Proposition: · Reduction in overall health budget · Reduction in test costs · Reduction in capex · Accessibility to underserved groups Commercial partners Group 2: HR Manager / Administrator in a company / business organization and (User) Employees. Value Proposition: · Ensure revenue realization · Continuation of business operations · Health and safety of employees